Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network

• NCT07228663

  Collaborator, Phase 3, Not yet recruiting, 100 people, 14 Nov 2025

• NCT05848713

  Collaborator, Phase 3, Recruiting, 4,000 people, 8 May 2023

• COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation

  Collaborator, Phase 4, Recruiting, 3,018 people, 24 Nov 2020

• NCT04243122

  Collaborator, Phase 2, Completed, 44 people, 28 Jan 2020

• NCT04153760

  Collaborator, Early phase 1, Completed, 257 people, 6 Nov 2019

• NCT04075240

  Collaborator, Phase 3, Completed, 5,429 people, 30 Aug 2019

• NCT03266783

  Collaborator, Phase 4, Completed, 2,760 people, 30 Aug 2017

• NCT02559856

  Collaborator, Phase 4, Completed, 71 people, 24 Sept 2015

Sources: clinicaltrials.gov